Kangxian Zhao
Wenzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Saikosaponin D Inhibited IL-1β Induced ATDC 5 Chondrocytes Apoptosis In Vitro and Delayed Articular Cartilage Degeneration in OA Model Mice In Vivo.
Journal: Frontiers in pharmacology
Published: December 30, 2021
Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway.
Journal: Drug design, development and therapy
Published: August 20, 2021
Pristimerin Inhibits Osteoclast Differentiation and Bone Resorption in vitro and Prevents Ovariectomy-Induced Bone Loss in vivo.
Journal: Drug design, development and therapy
Published: August 01, 2020
Correction to: Garcinol Suppresses IL-1β-Induced Chondrocyte Inflammation and Osteoarthritis via Inhibition of the NF-κB Signaling Pathway.
Journal: Inflammation
Published: June 17, 2020
Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.
Journal: Drug design, development and therapy
Published: April 04, 2020
Disulfiram suppressed ethanol promoted RANKL-induced osteoclastogenesis in vitro and ethanol-induced osteoporosis in vivo via ALDH1A1-NFATc1 axis.
Journal: Aging
Published: July 29, 2019
Vitexin suppresses RANKL-induced osteoclastogenesis and prevents lipopolysaccharide (LPS)-induced osteolysis.
Journal: Journal of cellular physiology
Published: November 13, 2018
Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
Journal: Journal of cellular physiology
Published: June 19, 2018
Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo.
Journal: Journal of cellular physiology
Published: April 05, 2018
Showing 1-10 of 10
Last Updated: 09/26/2026